LIFE - aTyr Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.2500
+0.0100 (+0.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close4.2400
Open4.3000
Bid4.2100 x 1000
Ask4.5800 x 800
Day's Range4.1600 - 4.3500
52 Week Range2.1300 - 7.6200
Volume34,887
Avg. Volume148,819
Market Cap39.781M
Beta (5Y Monthly)2.33
PE Ratio (TTM)N/A
EPS (TTM)-3.5200
Earnings DateMay 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Thomson Reuters StreetEvents

    Edited Transcript of LIFE earnings conference call or presentation 12-May-20 9:00pm GMT

    Q1 2020 aTyr Pharma Inc Earnings Call

  • GlobeNewswire

    aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II

    SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster and audio presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, which is being held June 22 – 24, 2020. The poster is available for browsing on the AACR website from June 22 – 24, 2020. The poster presents findings from a preclinical study, conducted in collaboration with Dr. Arthur M. Mercurio and his lab at the University of Massachusetts Medical School, demonstrating that aTyr has generated a panel of anti-human NRP2 monoclonal antibodies that have the potential to be developed for the clinical management of solid tumors.

  • GlobeNewswire

    aTyr Pharma Highlights New Literature Implicating Neuropilin Pathway In SARS-CoV-2 Infection

    Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry. Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen inflammatory responses. SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today highlighted new external research demonstrating the involvement of Neuropilin biology in SARS-CoV-2 infection.

  • GlobeNewswire

    aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

    SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has dosed the first patient in a Phase 2 study evaluating its lead therapeutic candidate, ATYR1923, in COVID-19 patients with severe respiratory complications. ATYR1923 is a potential first-in-class immunomodulator that has been shown preclinically to downregulate T-cell responses and improve inflammation and lung function. ATYR1923 is currently being evaluated in a Phase 1b/2a multi-center trial for patients with pulmonary sarcoidosis, a serious inflammatory lung disease.

  • Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
    Zacks

    Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know

    Atyr Pharma (LIFE) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Should You Buy aTyr Pharma Inc. (LIFE)?
    Insider Monkey

    Should You Buy aTyr Pharma Inc. (LIFE)?

    Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

  • Thomson Reuters StreetEvents

    Edited Transcript of LIFE earnings conference call or presentation 26-Mar-20 9:00pm GMT

    Q4 2019 aTyr Pharma Inc Earnings Call

  • GlobeNewswire

    aTyr Pharma to Present Poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

    SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will present an abstract in a poster session at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, which is being held June 22 – 24, 2020. The abstract is available online and will be included in an online-only Proceedings supplement to the AACR journal Cancer Research following the AACR Virtual Annual Meeting II. The poster is expected to be available on the AACR website on June 22, 2020.

  • Atyr Pharma (LIFE) Q1 Earnings and Revenues Surpass Estimates
    Zacks

    Atyr Pharma (LIFE) Q1 Earnings and Revenues Surpass Estimates

    Atyr Pharma (LIFE) delivered earnings and revenue surprises of 238.89% and 83.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19

    SAN DIEGO, May 12, 2020 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.

  • GlobeNewswire

    aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial Results

    SAN DIEGO, May 06, 2020 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.

  • GlobeNewswire

    aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine

    SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that two abstracts originally accepted for presentation at the 2020 ATS International Conference will be published in the ATS journal, American Journal of Respiratory and Critical Care Medicine. One abstract characterizes the molecular basis for ATYR1923’s immunomodulatory properties, including its ability to specifically and selectively bind to NRP2, a target that has been implicated in a broad range of immune-mediated diseases.

  • GlobeNewswire

    aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application

    SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate its lead therapeutic candidate, ATYR1923, in a Phase 2 study in COVID-19 patients with severe respiratory complications. “Many COVID-19 patients with severe disease experience serious, sometimes fatal, respiratory complications caused by an excessive inflammatory response in the lung, primarily driven by T-cells,” said Dr. Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “The inflammatory lung injury related to COVID-19 may be similar to that of interstitial lung diseases, or ILDs, for which ATYR1923 is currently being investigated.”

  • ACCESSWIRE

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of aTyr Pharma, Inc. - LIFE

    NEW YORK, NY / ACCESSWIRE / April 13, 2020 / Levi & Korsinsky announces it has commenced an investigation of aTyr Pharma, Inc. (NASDAQ:LIFE) concerning possible breaches of fiduciary duty. To obtain additional ...

  • GlobeNewswire

    aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update

    Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO, March 26, 2020 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company.

  • ACCESSWIRE

    aTyr Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 26, 2020 / aTyr Pharma, Inc. (NASDAQ:LIFE) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 26, 2020 at 5:00 PM ...

  • GlobeNewswire

    aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform

    SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company’s Hong Kong subsidiary, Pangu BioPharma Limited (Pangu), together with the Hong Kong University of Science and Technology (HKUST), has been awarded a grant of approximately $750,000 to build a high-throughput platform for the development of bi-specific antibodies. The two-year project is being funded by the Hong Kong Government’s Innovation and Technology Commission (ITC) under the Partnership Research Program (PRP).

  • GlobeNewswire

    aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th

    SAN DIEGO, March 19, 2020 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.

  • GlobeNewswire

    Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific Advisor

    SAN DIEGO, March 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the appointment of Arthur M. Mercurio, Ph.D. as a scientific advisor to the company. “We would like to welcome Dr. Mercurio as a scientific advisor to our company and we look forward to his contributions as we continue to advance our understanding of NRP2 and its role in the development and metastatic progression of cancers,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr.

  • GlobeNewswire

    aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering

    SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the underwriters of its previously announced public offering of common stock have fully exercised their over-allotment option resulting in the issuance of an additional 635,294 shares of common stock. The option was granted in connection with the public offering of 4,235,294 shares of common stock at a public offering price of $4.25 per share, which closed on February 10, 2020.

  • GlobeNewswire

    aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

    SAN DIEGO, March 03, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present an abstract in a poster session at the upcoming AACR Annual Meeting, which is being held April 24 – 29, 2020 at the San Diego Convention Center.

  • GlobeNewswire

    aTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology

    SAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a publication highlighting the essential role that histidyl tRNA synthetase (HARS) plays in the modulation of immune cell engagement in a broad range of disease states, including interstitial lung diseases. The paper, titled “Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses,” was published in the journal Cellular and Molecular Immunology.

  • Andreas Halvorsen Plunges Into aTyr Pharma
    GuruFocus.com

    Andreas Halvorsen Plunges Into aTyr Pharma

    Viking Global leader releases real-time trade in interstitial lung disease therapy provider Continue reading...

  • GlobeNewswire

    aTyr Pharma Announces Pricing of $18 million Underwritten Public Offering

    SAN DIEGO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the pricing of an underwritten public offering of 4,235,294 shares of its common stock at a price to the public of $4.25 per share. The offering is expected to close on or about February 10, 2020, subject to customary closing conditions. Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering.

  • Andreas Halvorsen Trims Adaptive Biotechnologies Stake
    GuruFocus.com

    Andreas Halvorsen Trims Adaptive Biotechnologies Stake

    The immune-driven biotech company went public last June Continue reading...